Motavizumab biosimilar

Drug Profile

Motavizumab biosimilar

Alternative Names: 3rd-generation anti-RSV MAb - MedImmune; MEDI-557; Mota-YTE; Motavizumab-YTE; RSV-YTE

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 30 Jun 2013 Discontinued - Phase-I for Respiratory syncytial virus infections in USA and United Kingdom (IV)
  • 01 Apr 2013 MedImmune completes a phase I trial in healthy volunteers in the United Kingdom (NCT01475305)
  • 11 May 2012 MedImmune completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01562938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top